Pulmonx strives to improve the lives of patients suffering from emphysema with its minimally-invasive, personalized technologies for interventional pulmonology.
The company’s commercially available portfolio includes the Zephyr Endobronchial Valve, the most-studied device for endoscopic lung volume reduction; the Chartis System, an assessment tool that identifies collateral ventilation; and the StratX Lung Analysis Platform, a cloud-based quantitative computed tomography (CT) analysis service. In limited release is AeriSeal, a foam-based lung sealant that is expected to significantly expand the treatable patient population for the company’s therapies.
This combination the assessment tools and therapeutics enables physicians to successfully predict outcomes and provide optimal treatment for each individual patient.
Used together, these technologies have been proven to improve pulmonary function, exercise capacity and quality of life in emphysema patients across multiple randomized controlled trials and in 12,000 patients worldwide. In fact, the Global Initiative for Chronic Obstructive Lung Disease(GOLD) now includes endobronchial valves in its management recommendations for chronic obstructive pulmonary disease (COPD)1.
The company is invested in building further clinical evidence across patient phenotypes to support the use of its technologies.
Pulmonx products are commercially available in Europe, Australia, Asia, Latin America and other countries worldwide. They are currently considered investigational in the United States. The Zephyr® Endobronchial Valve is an investigational device in the US, limited by US law to investigational use. StratX™ and AeriSeal® System are not available in the US.
|2017||Landmark data from 2 Multicenter RCTs presented showing substantial clinical benefits for both heterogeneous and homogeneous emphysema patients without collateral ventilation.|
|2016||GOLD includes Zephyr EBV in its COPD management recommendations|
|Respiration publishes positive 1-year outcomes from STELVIO, 1st Zephyr RCT using Chartis for patient selection|
|American Journal of Respiratory and Critical Care Medicine publishes results from IMPACT, 1st Zephyr multicenter RCT in patients with homogeneous emphysema using Chartis for patient selection|
|StratX Lung Analysis Platform launched|
|2015||10,000+ patients treated and 90+ publications|
|New England Journal of Medicine publishes positive 6-month results from STELVIO|
|The Lancet publishes 1st successful sham-controlled trial of any minimally invasive emphysema device (Zephyr), BeLieVeR-HIFi|
|2014||Acquisition of Aeris Therapeutics assets, including AeriSeal|
|2013||European Respiratory Journal publishes Chartis multicenter trial demonstrating ability to predict Zephyr responders|
|2011||European Respiratory Journal publishes 5-year data showing Zephyr sustained benefits and potential survival benefit|
|2010||New England Journal of Medicine publishes 1st randomized trial of Zephyr|
|2009||Chartis System receives CE Mark|
|2003||Zephyr receives CE Mark|
|2001||1st in man implant of Zephyr valve|
- GOLD (Global Initiative for Chronic Obstructive Lung Disease): Global Strategy for the Diagnosis, Management and Prevention of COPD – 2017 report